Hypertonic Saline Use in Preeclampsia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Abimbola Aina, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00181077
First received: September 10, 2005
Last updated: September 21, 2012
Last verified: September 2012

September 10, 2005
September 21, 2012
June 2003
April 2006   (final data collection date for primary outcome measure)
Fluid input to output ratios
Same as current
Complete list of historical versions of study NCT00181077 on ClinicalTrials.gov Archive Site
laboratory evaluation of inflammatory parameters (platelet count, IL-1, IL-6), liver enzymes, weight
Same as current
Not Provided
Not Provided
 
Hypertonic Saline Use in Preeclampsia
Hypertonic Saline Use for Volume Expansion in Postpartum Preeclampsia

To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.

Our patient population will consist of postpartum women who were diagnosed with preeclampsia in the antepartum period. Our goal is to enroll ten patients in the treated group and ten patients in the control group. The treatment group will have a 2% buffered hypertonic saline solution infused at 30 mL/hr in addition to receiving magnesium sulfate for seizure prophylaxis. The control group will receive the currently practiced regimen of infusion of a Lactated Ringer's solution at 75cc/hr. Both groups will be monitored on our Labor and Delivery unit as is the norm for any patient on a magnesium sulfate infusion. They will receive routine nursing care and hourly collaborative team assessments by the nurses and the physicians for signs of magnesium toxicity. Urine input/output ratios are evaluated on an hourly basis and a lung examination is performed to assess for pulmonary edema. A pulse oximeter will be used to obtain an hourly assessment of the patient's oxygenation status.

Both groups will have blood work evaluation every six hours for platelet count, electrolytes, liver enzymes, interleukin-1 and interleukin-6 (as markers of inflammation). We will collect information on patient symptoms regarding headache, visual changes and epigastric pain at 4-hour intervals and obtain the patient's weight immediately postpartum as well as at 24-hour intervals. Magnesium sulfate infusions will be discontinued at 24 hours postpartum or later at the discretion of the treating physician. No antihypertensive medications will be withheld from either group. Blood pressure will be obtained in the patients at the current interval of 60 minutes.

Hypertonic saline will be infused until the patient is 24 hours postpartum. Our primary outcome variable is the ratio of fluid intake to urine output. Data will be collected during the length of stay on our Labor and Delivery unit before the patient meets criteria for transfer to our postpartum unit, and their overall hospital stay.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Preeclampsia
Drug: 2% buffered hypertonic saline administration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 2006
April 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women must have satisfied conditions for the diagnosis of preeclampsia (BP > 140/90, proteinuria ≥ 2+ or 300 mg in 24 hours)
  • Women must have creatinine level below 1.6 mg/dL
  • Women must have delivered their infant(s) prior to initiating therapy
  • Women must be English-speaking
  • Women must be medically stable at the time of entry into the study
  • Women must be over the legal consenting age of 18 years
  • Women must be consented prior to the administration of narcotics or other medications that may interfere with ability to give informed consent
  • If not consented at the time of admission to Labor and Delivery, women must be comfortable enough with their contractions to complete the informed consent process without duress, or must be comfortable with regional anesthesia
  • Women on magnesium sulfate will be eligible for entry after assessment of level of consciousness is deemed sufficient to give informed consent

Exclusion Criteria:

  • Women not able to understand the study because of language barriers or significant learning impairment
  • Women less than 18 years of age
  • Women who are medically unstable prior to recruitment or in whom expeditious delivery is warranted
  • Women who have developed eclampsia (or seizures as a result of their preeclamptic condition)
  • Women who have not consented prior to the administration of narcotics or other medications that may interfere with their ability to give informed consent
  • Women whose pain severity in labor is such that they cannot participate in informed consent
  • Women with a pre-existing cardiomyopathy
  • Women with a sodium level < 130, or > 150 mEq/L
  • Women with a creatinine level greater than 1.6 mg/dL
  • Women with co-morbid conditions that affect renal function i.e. lupus nephritis, diabetic nephropathy, or pre-existing hypertensive kidney disease
  • Women whose level of consciousness on magnesium sulfate is deemed insufficient to give informed consent
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00181077
03--03-13-06
No
Abimbola Aina, Johns Hopkins University
Johns Hopkins University
Not Provided
Principal Investigator: Abimbola Aina-Mumuney, MD Johns Hopkins University
Johns Hopkins University
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP